Two lung cancer drugs approved and one rejected for NHS Scotland

An immunotherapy and a targeted treatment have been recommended for use on the NHS in Scotland, but a third treatment was rejected. The Scottish Medical Consortium (SMC) approved the use of two new treatment options—dacomitinib (Vizimpro) and pembrolizumab (Keytruda) – for some patients with non small cell lung cancer. But a third lung cancer drug, osimertinib, has been rejected by […]

Read more

Chaotic talks show challenge of reaching opioid settlement

For months, the judge overseeing national litigation over the opioids crisis urged all sides to reach a settlement that could end thousands of lawsuits filed by state and local governments. But the chaotic developments this week in the case against OxyContin maker Purdue Pharma underscore how difficult that goal is. By Thursday, half of the nation’s state attorneys general said […]

Read more

Compound offers prospects for preventing acute kidney failure

Russian researchers from the Moscow Institute of Physics and Technology, the Institute of Cell Biophysics, and elsewhere have shown an antioxidant compound known as peroxiredoxin to be effective in treating kidney injury in mice. The study in Cell and Tissue Research reports tripled survival rates in test animals treated with the chemical prior to sustaining an ischemia reperfusion injury. The […]

Read more

Drug designed to treat metastatic pancreatic cancer may help extend life

A drug developed by researchers at the Renaissance School of Medicine at Stony Brook University that targets enzymes involved in the development of pancreatic cancer cells is showing promise for improved treatment of metastatic pancreatic cancer. The drug, called CPI-613 (known as Devimistat), is being combined with the standard chemotherapy regimen (FOLFIRINOX) to treat pancreatic cancer. The Stony Brook Cancer […]

Read more

Post opioid-overdose interventions emerge in US

Opioid-related deaths continue to take the lives of thousands in the U.S. each year, with non-fatal opioid overdoses as a significant risk factor for a subsequent fatal overdose. Post-overdose interventions are emerging in affected communities, using what support systems are available to assist in the program design. Survivors often do not seek treatment or overdose risk reduction services immediately after […]

Read more

Study shows hazardous patterns of prescription opioid misuse in the US

Among adults aged 18 years and older, 31 percent used prescription opioids only as prescribed by a physician medically and 4 percent misused them. Thus, the overwhelming majority (88 percent) of all past-12-month prescription opioid users used the drugs for medical purposes only, according to a new study at Columbia University Mailman School of Public Health and Vagelos College of […]

Read more

Research explores the use of new psychoactive substances by young people

A research study into New Psychoactive Substances (NPS)—formerly referred to as ‘legal highs’—provides new evidence about why young people were attracted to the drugs, and the health and social risks associated with taking them. The study was carried out by an interdisciplinary team of researchers from Queen’s University Belfast. The research findings recommend support using existing evidence-based interventions among young […]

Read more

New drug shows encouraging survival in pancreatic cancer

A clinical trial testing a new drug in pancreatic cancer had promising initial results, report researchers from the University of Michigan Rogel Cancer Center. A phase 1 clinical trial looked at AZD1775, an inhibitor designed to block an enzyme called Wee1, which plays a role in DNA damage repair. The trial builds on almost 20 years of research at U-M […]

Read more

Prescription drug misuse common in high schoolers

(HealthDay)—Misuse of prescription drugs is common among high school students, and those misusing prescription drugs frequently obtain them from multiple sources, according to two studies published in the July issue of the Journal of the American Academy of Child and Adolescent Psychiatry. Ty S. Schepis, Ph.D., from Texas State University in San Marcos, used data from the 2009 to 2014 […]

Read more
1 12 13 14 15 16 24